Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vivesto AB ( (SE:VIVE) ) has provided an update.
Vivesto AB has published an information document for a fully covered rights issue of approximately SEK 53.8 million, offering existing shareholders one new share at SEK 0.10 for each share held, with trading in subscription rights on Nasdaq Stockholm from 8–19 January 2026 and a subscription period running to 22 January 2026. The capital raise, backed by subscription commitments and guarantee undertakings from major shareholders and external investors, is intended to fund ongoing Paccal Vet pilot and dose-determination studies in dogs and cats, preclinical and pilot studies for Cantrixil, partial repayment of loans to Arwidsro, and general corporate purposes, with the company assessing that the proceeds will finance operations into the second half of 2027.
More about Vivesto AB
Vivesto AB is a Swedish life science company focused on developing veterinary oncology treatments, including its Paccal Vet program for dogs and cats, and preclinical and clinical development of the cancer drug candidate Cantrixil. The company is listed on Nasdaq Stockholm and targets the animal health and veterinary pharmaceuticals market.
Average Trading Volume: 927,935
Technical Sentiment Signal: Sell
Current Market Cap: SEK72.64M
Find detailed analytics on VIVE stock on TipRanks’ Stock Analysis page.